Clinical Trial Update: Staccato Loxapine Pulmonary Safety in Patients With COPD [Phase 1]

View source ↗

Summary

Phase 1 trial update assessing the pulmonary safety of inhaled loxapine (Staccato) in patients with chronic obstructive pulmonary disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Staccato Loxapine (loxapine)

Snippet

Sponsor: Alexza Pharmaceuticals, Inc. | Conditions: Chronic Obstructive Pulmonary Disease | Phase 1 | Status: COMPLETED